SEHK:1050
SEHK:1050Electronic

Asian Market Insights: 3 Penny Stocks With Market Caps Over US$20M

Amidst global concerns about AI valuations and economic uncertainties, Asian markets have mirrored some of the cautious sentiment seen in other regions. For investors interested in exploring smaller or newer companies, penny stocks continue to present intriguing opportunities despite their somewhat dated terminology. These stocks, often representing under-the-radar growth potential at lower price points, can offer significant upside when backed by strong financial health and solid fundamentals.
SEHK:981
SEHK:981Semiconductor

A Fresh Look at SMIC (SEHK:981) Valuation Following Higher Sales and Upbeat Q4 Guidance

Semiconductor Manufacturing International (SEHK:981) just released its latest earnings, showing increased sales and net income for the nine months ending September 30, 2025. The company also projected stable or slightly higher revenue for the upcoming quarter. See our latest analysis for Semiconductor Manufacturing International. On the heels of stronger sales and upbeat guidance, Semiconductor Manufacturing International’s 1-year total shareholder return stands out at 167.9%, showing...
SEHK:799
SEHK:799Entertainment

Asian Market Insights: Top Penny Stocks To Consider In November 2025

Amid global market fluctuations and AI-related concerns, the Asian markets have also experienced their share of volatility, with particular focus on technology valuations and economic stimulus measures. Despite these challenges, investors continue to explore opportunities in various sectors, including those offered by penny stocks. These smaller or newer companies can present significant potential when backed by solid financials, offering a chance to uncover hidden value in an ever-evolving...
SEHK:1288
SEHK:1288Banks

How Investors May Respond To Agricultural Bank of China (SEHK:1288) Strengthening Capital Base with RMB35 Billion Tier 2 Notes

On November 20, 2025, Agricultural Bank of China completed the issuance of RMB35.0 billion in Tier 2 capital notes across 10-year and 15-year tranches in the National Interbank Bond Market, with interest rates of 2.14% and 2.40% respectively and conditional redemption rights at specified anniversaries. This substantial capital raising strengthens the bank's regulatory capital base and highlights both robust investor demand and consistent regulatory support for its growth and risk management...
SEHK:175
SEHK:175Auto

Geely Auto (SEHK:175): Exploring Valuation After Recent Share Price Pullback

Geely Automobile Holdings (SEHK:175) shares have shown some intriguing movement over the past month, catching the eye of investors tracking trends in the fast-changing Chinese automotive sector. With recent shifts in performance, some investors are taking a closer look. See our latest analysis for Geely Automobile Holdings. After a strong rally earlier in the year, Geely’s share price has cooled recently with a 12% dip over the past month. Still, total shareholder returns stand at an...
SEHK:9863
SEHK:9863Auto

Should Leapmotor’s Addition to the Hang Seng TECH Index Prompt Action From SEHK:9863 Investors?

Zhejiang Leapmotor Technology recently announced its inclusion as a constituent stock of the Hang Seng TECH Index, effective December 8, 2025, marking an important recognition of its innovations in the technology and new energy vehicle space. This development is anticipated to expand the company's investor base, improve trading liquidity, and increase market visibility among global investors. We'll examine how Leapmotor's upcoming addition to the Hang Seng TECH Index could reinforce its...
SEHK:1177
SEHK:1177Pharmaceuticals

China Approves LM-350 Clinical Trials; Could Be a Game Changer for Sino Biopharm (SEHK:1177)

On November 18, 2025, Sino Biopharmaceutical announced that its subsidiary LaNova Medicines received clinical trial approval in China for LM-350, a CDH17-targeting antibody-drug conjugate aimed at treating multiple gastrointestinal cancers. This regulatory milestone marks further progress in Sino Biopharmaceutical's efforts to address significant unmet medical needs in the oncology sector through its innovative pipeline. We’ll examine how this clinical trial approval for LM-350 shapes Sino...
SEHK:6181
SEHK:6181Luxury

Laopu Gold's Dividend Policy Approval Might Change The Case For Investing In Laopu Gold (SEHK:6181)

On November 18, 2025, Laopu Gold Co., Ltd. announced shareholder approval of an interim dividend of RMB 9.59 per share for the first half of the year, with payment scheduled for January 15, 2026 in both RMB and HKD to eligible shareholders. The approval of a formal dividend policy and amendments to the Articles of Association signify the company's focus on enhanced shareholder returns and governance practices. We will explore how the establishment of a consistent dividend policy shapes Laopu...